UK Markets closed

Allarity Therapeutics A/S TO 2 (ALLR-TO-2.ST)

Stockholm - Stockholm Real-time price. Currency in SEK
Add to watchlist
0.0026-0.0016 (-38.10%)
At close: 5:04PM CEST
Full screen
Previous close0.0042
Open0.0050
Bid0.0050 x N/A
Ask0.0060 x N/A
Day's range0.0014 - 0.0060
52-week range0.0014 - 0.0060
Volume1,264,558
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Allarity Therapeutics Presents Dovitinib Survival Data from DRP® Screened RCC Patients at ESMO 2021 Virtual Congress

    Patient selection using DRP® score of 50% resulted in a median survival of 15.0 monthPatient selection using DRP® score of 67% resulted in a median survival of 20.6 months Press Release Hørsholm, Denmark (September 16, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announced validation results for its Dovitinib DRP® companion diagnostic utilizing data from Novartis’ prior Phase III trial of dovitinib in renal cell carcinoma (RCC), which will be included in a poster present

  • Globe Newswire

    Update: Allarity Therapeutics Receives Approximately SEK 23.3 Million (US $2.7 Million) from Subscription to Warrants of Series ALLR TO 2 and TO 3

    Subscription is approximately 9.5 percent of total outstanding TO 3 warrants Allarity’s Chairman of the Board and largest shareholder (Sass & Larsen ApS) participated in the subscription Press ReleaseHørsholm, Denmark (September 15, 2021) CORRECTION: The press release that the company published on September 14, 2021, at 23:06 CEST, contained an incomplete computation of the number of subscribed shares. The correct number of subscribed shares shall be 13,719,266. Consequently, the amount raised i

  • Globe Newswire

    Allarity Therapeutics Receives Approximately SEK 16.5 Million (US $1.9 Million) from Subscription to Warrants of Series ALLR TO 3

    Subscription is approximately 6.7 percent of total outstanding TO 3 warrants Allarity’s Chairman of the Board and largest shareholder (Sass & Larsen ApS) participated in the subscription Press Release Hørsholm, Denmark (September 14, 2021) – Allarity Therapeutics A/S (“Allarity” or the “Company”) today announces the outcome of the exercise of the warrants of series ALLR TO 3 that were issued in connection with the Company’s issue of units in June 2021. In total, 9,719,266 warrants of series TO 3